News

JNJ tops Q2 earnings and sales estimates, driven by key drug growth, and raises its 2026 outlook despite a slight MedTech sales miss.

ABBV stock rallies 9% YTD as Skyrizi and Rinvoq offset Humira declines, but can its pipeline, neuroscience growth and Apogee deal sustain long-term momentum?

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...

Year over year wholesale inflation pulls back to +5.5%, 100 bps lower than last month's initial print.

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.

Walmart and Johnson & Johnson both beat estimates this quarter, but the way each giant is spending its capital tells two completely different stories about where defensive investing actually pays off right now.

Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expect

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]

While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

News of the day for July 15, 2026

US equity futures were edging higher pre-bell Wednesday as traders considered the latest inflation d

Picture two retirees with identical $1.5 million portfolios throwing off $80,000 a year in taxable portfolio income. One lives in Naples, Florida. The other lives in San Diego. If that income is taxed as ordinary income and falls in California’s 9.3% bracket, the California retiree could lose about $7,440 a year to state income tax ... The State Tax Trap: Where the Same Retirement Portfolio Buys You Thousands More Every Year

The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.11% and +0.53%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.

Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.

Chip-gear giant ASML rose with the Nasdaq and AI stocks at key levels. Oil prices topped $80 a barrel on new U.S. attacks vs. Iran.

Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.

By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster

Eight thousand dollars a month is the kind of retirement income target that looks simple until the yield math starts moving underneath it. It translates to $96,000 a year, but the portfolio needed to produce that income can vary by well over $1 million depending on whether the investor accepts a 3.5% yield, a 6% ... What It Takes to Earn $8,000 a Month From Dividends Without Chasing Yield

Stocks looked set to rise again on Wednesday, building on gains from the previous session that were powered by a solid start to the second-quarter earnings season and cooler-than-expected inflation data. Nasdaq 100 futures added 0.4%. Dow Jones Industrial Average futures rose 81 points, or 0.2%.

↗️ PayPal Holdings (PYPL): Shares of the digital-payments company surged more than 15% in premarket trading following a Reuters report that payments processor Stripe and private-equity firm Advent offered to buy it for more than $53 billion.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

The Nasdaq and AI stocks rallied, but still face key resistance. Goldman and CrowdStrike make big bullish moves.

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.